Generalized epilepsy with febrile seizures plus: Difference between revisions
No edit summary |
CSV import |
||
| Line 1: | Line 1: | ||
{{SI}} | |||
{{Infobox medical condition | |||
| name = Generalized epilepsy with febrile seizures plus | |||
| image = [[File:SCN2A_GEFS_plus.png|alt=Image depicting the SCN2A gene associated with GEFS+]] | |||
| caption = Image depicting the SCN2A gene associated with GEFS+ | |||
| field = [[Neurology]] | |||
| symptoms = [[Febrile seizures]], [[generalized tonic-clonic seizures]], [[myoclonic seizures]], [[absence seizures]] | |||
| onset = [[Infancy]] or [[early childhood]] | |||
| duration = [[Chronic (medicine)|Chronic]] | |||
| causes = [[Genetic mutation]]s in [[SCN1A]], [[SCN1B]], [[SCN2A]], [[GABRG2]], [[GABRD]] | |||
| risks = Family history of [[epilepsy]] | |||
| diagnosis = [[Electroencephalogram|EEG]], [[genetic testing]] | |||
| differential = [[Dravet syndrome]], [[Lennox-Gastaut syndrome]] | |||
| treatment = [[Anticonvulsant]]s, [[ketogenic diet]], [[vagus nerve stimulation]] | |||
| prognosis = Variable, often improves with age | |||
| frequency = Rare | |||
}} | |||
'''Generalized Epilepsy with Febrile Seizures Plus''' (GEFS+) is a familial epilepsy syndrome characterized by a spectrum of seizure types, including febrile seizures and afebrile generalized seizures. It is a genetic disorder that affects the nervous system, often beginning in infancy or early childhood. | '''Generalized Epilepsy with Febrile Seizures Plus''' (GEFS+) is a familial epilepsy syndrome characterized by a spectrum of seizure types, including febrile seizures and afebrile generalized seizures. It is a genetic disorder that affects the nervous system, often beginning in infancy or early childhood. | ||
== Clinical Features == | == Clinical Features == | ||
GEFS+ is marked by a variety of seizure types. The most common are [[febrile seizures]], which are convulsions triggered by fever in young children. In addition to febrile seizures, individuals with GEFS+ may experience other types of seizures, such as [[absence seizures]], [[myoclonic seizures]], and [[tonic-clonic seizures]]. | GEFS+ is marked by a variety of seizure types. The most common are [[febrile seizures]], which are convulsions triggered by fever in young children. In addition to febrile seizures, individuals with GEFS+ may experience other types of seizures, such as [[absence seizures]], [[myoclonic seizures]], and [[tonic-clonic seizures]]. | ||
== Genetics == | == Genetics == | ||
GEFS+ is primarily caused by mutations in genes that encode for ion channels, which are crucial for the proper functioning of neurons. The most commonly affected genes include: | GEFS+ is primarily caused by mutations in genes that encode for ion channels, which are crucial for the proper functioning of neurons. The most commonly affected genes include: | ||
=== SCN1A === | === SCN1A === | ||
The [[SCN1A]] gene encodes the alpha subunit of the voltage-gated sodium channel. Mutations in this gene are a major cause of GEFS+ and are also associated with more severe epilepsy syndromes such as [[Dravet syndrome]]. | The [[SCN1A]] gene encodes the alpha subunit of the voltage-gated sodium channel. Mutations in this gene are a major cause of GEFS+ and are also associated with more severe epilepsy syndromes such as [[Dravet syndrome]]. | ||
=== SCN2A === | === SCN2A === | ||
The [[SCN2A]] gene encodes another subunit of the sodium channel. Mutations in SCN2A can lead to a range of epilepsy phenotypes, including GEFS+. | The [[SCN2A]] gene encodes another subunit of the sodium channel. Mutations in SCN2A can lead to a range of epilepsy phenotypes, including GEFS+. | ||
=== GABRG2 === | === GABRG2 === | ||
The [[GABRG2]] gene encodes a subunit of the GABA_A receptor, which is involved in inhibitory neurotransmission. Mutations in this gene can disrupt normal neuronal inhibition, contributing to the development of seizures. | The [[GABRG2]] gene encodes a subunit of the GABA_A receptor, which is involved in inhibitory neurotransmission. Mutations in this gene can disrupt normal neuronal inhibition, contributing to the development of seizures. | ||
=== SCN1B === | === SCN1B === | ||
[[File:Sodium_channel_beta_GEFS_plus.png|thumb| | [[File:Sodium_channel_beta_GEFS_plus.png|thumb|left|Illustration of the sodium channel beta subunit related to GEFS+]] | ||
The [[SCN1B]] gene encodes the beta subunit of the sodium channel. Mutations in SCN1B can alter the function of sodium channels, leading to increased neuronal excitability and seizures. | The [[SCN1B]] gene encodes the beta subunit of the sodium channel. Mutations in SCN1B can alter the function of sodium channels, leading to increased neuronal excitability and seizures. | ||
== Diagnosis == | == Diagnosis == | ||
The diagnosis of GEFS+ is based on clinical evaluation, family history, and genetic testing. Genetic testing can identify mutations in the genes associated with the syndrome, confirming the diagnosis. | The diagnosis of GEFS+ is based on clinical evaluation, family history, and genetic testing. Genetic testing can identify mutations in the genes associated with the syndrome, confirming the diagnosis. | ||
== Treatment == | == Treatment == | ||
Treatment for GEFS+ typically involves the use of [[antiepileptic drugs]] (AEDs) to control seizures. The choice of medication depends on the specific types of seizures experienced by the individual. In some cases, lifestyle modifications and avoidance of seizure triggers may also be recommended. | Treatment for GEFS+ typically involves the use of [[antiepileptic drugs]] (AEDs) to control seizures. The choice of medication depends on the specific types of seizures experienced by the individual. In some cases, lifestyle modifications and avoidance of seizure triggers may also be recommended. | ||
== Prognosis == | == Prognosis == | ||
The prognosis for individuals with GEFS+ varies. Some individuals may outgrow their seizures, while others may continue to experience seizures into adulthood. The severity of the condition can also vary widely among affected individuals. | The prognosis for individuals with GEFS+ varies. Some individuals may outgrow their seizures, while others may continue to experience seizures into adulthood. The severity of the condition can also vary widely among affected individuals. | ||
== See Also == | |||
== | |||
* [[Epilepsy]] | * [[Epilepsy]] | ||
* [[Febrile seizures]] | * [[Febrile seizures]] | ||
* [[Dravet syndrome]] | * [[Dravet syndrome]] | ||
* [[Ion channel]] | * [[Ion channel]] | ||
[[Category:Epilepsy]] | [[Category:Epilepsy]] | ||
[[Category:Genetic disorders]] | [[Category:Genetic disorders]] | ||
Latest revision as of 03:51, 6 April 2025
Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's medical weight loss NYC, sleep center NYC
Philadelphia medical weight loss and Philadelphia sleep clinics
| Generalized epilepsy with febrile seizures plus | |
|---|---|
| Image depicting the SCN2A gene associated with GEFS+ | |
| Synonyms | N/A |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Febrile seizures, generalized tonic-clonic seizures, myoclonic seizures, absence seizures |
| Complications | N/A |
| Onset | Infancy or early childhood |
| Duration | Chronic |
| Types | N/A |
| Causes | Genetic mutations in SCN1A, SCN1B, SCN2A, GABRG2, GABRD |
| Risks | Family history of epilepsy |
| Diagnosis | EEG, genetic testing |
| Differential diagnosis | Dravet syndrome, Lennox-Gastaut syndrome |
| Prevention | N/A |
| Treatment | Anticonvulsants, ketogenic diet, vagus nerve stimulation |
| Medication | N/A |
| Prognosis | Variable, often improves with age |
| Frequency | Rare |
| Deaths | N/A |
Generalized Epilepsy with Febrile Seizures Plus (GEFS+) is a familial epilepsy syndrome characterized by a spectrum of seizure types, including febrile seizures and afebrile generalized seizures. It is a genetic disorder that affects the nervous system, often beginning in infancy or early childhood.
Clinical Features[edit]
GEFS+ is marked by a variety of seizure types. The most common are febrile seizures, which are convulsions triggered by fever in young children. In addition to febrile seizures, individuals with GEFS+ may experience other types of seizures, such as absence seizures, myoclonic seizures, and tonic-clonic seizures.
Genetics[edit]
GEFS+ is primarily caused by mutations in genes that encode for ion channels, which are crucial for the proper functioning of neurons. The most commonly affected genes include:
SCN1A[edit]
The SCN1A gene encodes the alpha subunit of the voltage-gated sodium channel. Mutations in this gene are a major cause of GEFS+ and are also associated with more severe epilepsy syndromes such as Dravet syndrome.
SCN2A[edit]
The SCN2A gene encodes another subunit of the sodium channel. Mutations in SCN2A can lead to a range of epilepsy phenotypes, including GEFS+.
GABRG2[edit]
The GABRG2 gene encodes a subunit of the GABA_A receptor, which is involved in inhibitory neurotransmission. Mutations in this gene can disrupt normal neuronal inhibition, contributing to the development of seizures.
SCN1B[edit]
The SCN1B gene encodes the beta subunit of the sodium channel. Mutations in SCN1B can alter the function of sodium channels, leading to increased neuronal excitability and seizures.
Diagnosis[edit]
The diagnosis of GEFS+ is based on clinical evaluation, family history, and genetic testing. Genetic testing can identify mutations in the genes associated with the syndrome, confirming the diagnosis.
Treatment[edit]
Treatment for GEFS+ typically involves the use of antiepileptic drugs (AEDs) to control seizures. The choice of medication depends on the specific types of seizures experienced by the individual. In some cases, lifestyle modifications and avoidance of seizure triggers may also be recommended.
Prognosis[edit]
The prognosis for individuals with GEFS+ varies. Some individuals may outgrow their seizures, while others may continue to experience seizures into adulthood. The severity of the condition can also vary widely among affected individuals.
